Dr. Michael Levin, investigator for the phase three trial of the first COVID-19 vaccine developed in the U.S. by the National Institute of Health and Moderna Inc., talks about what health experts hope to learn from the trial. (Rachel Aston/Las Vegas Review-Journal)